DK1929297T3 - Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf - Google Patents
Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse herafInfo
- Publication number
- DK1929297T3 DK1929297T3 DK06815711.4T DK06815711T DK1929297T3 DK 1929297 T3 DK1929297 T3 DK 1929297T3 DK 06815711 T DK06815711 T DK 06815711T DK 1929297 T3 DK1929297 T3 DK 1929297T3
- Authority
- DK
- Denmark
- Prior art keywords
- biomarkers
- methods
- disseminated sclerosis
- disseminated
- sclerosis
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72217205P | 2005-09-29 | 2005-09-29 | |
PCT/US2006/037924 WO2007041245A2 (en) | 2005-09-29 | 2006-09-29 | Biomarkers for multiple sclerosis and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1929297T3 true DK1929297T3 (da) | 2013-03-04 |
Family
ID=37906719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06815711.4T DK1929297T3 (da) | 2005-09-29 | 2006-09-29 | Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100062471A1 (da) |
EP (2) | EP2517727A3 (da) |
DK (1) | DK1929297T3 (da) |
SI (1) | SI1929297T1 (da) |
WO (1) | WO2007041245A2 (da) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
KR101314461B1 (ko) | 2004-05-12 | 2013-10-07 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 감염 치료를 위한 겔솔린의 용도 |
DK2002258T3 (da) * | 2006-03-15 | 2018-01-02 | Brigham & Womens Hospital Inc | Anvendelse af gelsolin til behandling af multipel sklerose og diagnosticering af neurologiske sygdomme |
PT3279663T (pt) | 2006-03-15 | 2021-09-24 | Brigham & Womens Hospital Inc | Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias |
EP2064547A4 (en) * | 2006-09-18 | 2010-03-17 | Multiple Sclerosis Res Ct Of N | FETUINE-A AS A BIOMARKER FOR MULTIPLE SCLEROSIS |
EP1988175A1 (en) * | 2007-05-03 | 2008-11-05 | Bayer Schering Pharma Aktiengesellschaft | Predictive RNA profiles |
DE102007041657A1 (de) * | 2007-09-03 | 2009-03-05 | Protagen Ag | Markersequenzen für Multiple Sklerose und deren Verwendung |
ES2634263T3 (es) | 2008-01-25 | 2017-09-27 | The General Hospital Corporation | Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal |
ES2763537T3 (es) * | 2008-09-16 | 2020-05-29 | Beckman Coulter Inc | Diagrama de árbol interactivo para datos de citometría de flujo |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
ES2602977T3 (es) * | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
EP4265267A3 (en) | 2010-10-19 | 2024-01-17 | Op-T LLC | Peptides for modulating t-cell activity and uses thereof |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US8945935B2 (en) | 2011-08-04 | 2015-02-03 | Technion Research & Development Foundation Ltd. | Diagnosing, prognosing and monitoring multiple sclerosis |
US20160040236A1 (en) * | 2013-03-15 | 2016-02-11 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
EP2972393A4 (en) * | 2013-03-15 | 2016-10-26 | Sera Prognostics Inc | BIOMARKERS AND METHOD FOR PREDICTING PREECLAMPSIA |
CA2917917A1 (en) * | 2013-07-25 | 2015-01-29 | Theranos, Inc. | Systems and methods for a distributed clinical laboratory |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
WO2015088915A1 (en) | 2013-12-09 | 2015-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
WO2015148389A2 (en) * | 2014-03-23 | 2015-10-01 | The Regents Of The University Of Colorado | Diagnosis of multiple sclerosis in human and animal subjects |
WO2016040861A1 (en) * | 2014-09-12 | 2016-03-17 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
SI3307296T1 (sl) | 2015-06-15 | 2022-04-29 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj |
US10392665B2 (en) | 2015-06-19 | 2019-08-27 | Sera Prognostics, Inc. | Biomarker pairs for predicting preterm birth |
EP4019643A1 (en) * | 2015-09-23 | 2022-06-29 | Oklahoma Medical Research Foundation | Biomarkers for assessing subjects with multiple sclerosis |
WO2017058999A2 (en) * | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal |
AU2017286979B2 (en) | 2016-07-01 | 2023-04-27 | Dignity Health | Diagnostic or predictor of relapsing remitting multiple sclerosis |
AU2018317902A1 (en) | 2017-08-18 | 2020-03-05 | Sera Prognostics, Inc. | Pregnancy clock proteins for predicting due date and time to birth |
US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
EP4135742A2 (en) | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
AU2021336985A1 (en) * | 2020-09-04 | 2023-05-18 | Octave Bioscience, Inc. | Biomarkers for predicting multiple sclerosis disease progression |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432662B1 (en) | 1997-04-15 | 2002-08-13 | Pierce Chemical Company | Assay of peroxidase activity |
AU2001292846A1 (en) * | 2000-09-20 | 2002-04-29 | Surromed, Inc. | Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders |
US6835927B2 (en) | 2001-10-15 | 2004-12-28 | Surromed, Inc. | Mass spectrometric quantification of chemical mixture components |
AU2003263409B2 (en) * | 2002-08-02 | 2010-05-27 | Glycominds Ltd. | Method for diagnosing multiple sclerosis |
-
2006
- 2006-09-29 EP EP12161896.1A patent/EP2517727A3/en not_active Withdrawn
- 2006-09-29 WO PCT/US2006/037924 patent/WO2007041245A2/en active Application Filing
- 2006-09-29 EP EP06815711A patent/EP1929297B1/en not_active Not-in-force
- 2006-09-29 DK DK06815711.4T patent/DK1929297T3/da active
- 2006-09-29 SI SI200631526T patent/SI1929297T1/sl unknown
- 2006-09-29 US US12/088,228 patent/US20100062471A1/en not_active Abandoned
-
2014
- 2014-02-27 US US14/192,356 patent/US20150031562A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1929297A4 (en) | 2010-02-24 |
EP2517727A3 (en) | 2013-10-30 |
US20100062471A1 (en) | 2010-03-11 |
EP1929297A2 (en) | 2008-06-11 |
EP2517727A2 (en) | 2012-10-31 |
WO2007041245A2 (en) | 2007-04-12 |
WO2007041245A3 (en) | 2009-05-07 |
SI1929297T1 (sl) | 2013-06-28 |
US20150031562A1 (en) | 2015-01-29 |
EP1929297B1 (en) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1929297T3 (da) | Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf | |
DK1934179T3 (da) | Fremgangsmåder og mellemprodukter | |
ATE429585T1 (de) | Rohrleitung | |
DK2371958T3 (da) | HIDTIL UKENDTE siRNA OG FREMGANGSMÅDER TIL ANVENDELSE DERAF | |
ATE446090T1 (de) | Thiadiazolidinone als gsk3-inhibitoren | |
DK1919514T3 (da) | Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf | |
DE602005020968D1 (de) | n dafür | |
DE602005005527D1 (de) | Verschlussdüse | |
DK2479259T3 (da) | Multi-kryokonserverede hepatocytter og fremgangsmåder til fremstillilng deraf | |
ITPD20060384A1 (it) | Dispositivo di manipolazione | |
DK1817055T3 (da) | Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf | |
DE602005019525D1 (de) | Verschlussdüse | |
DK1976884T3 (da) | Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf. | |
NO20043033D0 (no) | Rorplassering | |
DK2032764T3 (da) | Vejbelægningsmarkeringsmønsker og fremgangsmåde til dets påføring | |
DK1955066T3 (da) | Membran-assay-fremgangsmåde | |
DE602005008322D1 (de) | Abtastschaltung | |
DE602006021285D1 (de) | Mikrotomklinge | |
FI20050681A0 (fi) | Paikoitusmenetelmä | |
NO20054981D0 (no) | Dreieanordning til mobel | |
DK1962960T3 (da) | Fremgangsmåde til mikornisering | |
FI20045242A0 (fi) | Tiedon arviointi | |
DK1761221T3 (da) | Fastgørelsesmekanisme til stomiposer | |
DE102005012312B8 (de) | Montagelinie und -verfahren | |
NO20044457D0 (no) | Kombi-Brodd og Kombi-Brodd-System for Rollotorer |